Evaluation of the effectiveness and safety of Sofosbuvir plus Daclatasvir in the treatment for HCV or HIV/HCV with hemophilia

Trial Profile

Evaluation of the effectiveness and safety of Sofosbuvir plus Daclatasvir in the treatment for HCV or HIV/HCV with hemophilia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2016

At a glance

  • Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
  • Indications Haemophilia; Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2016 Due to common secondary identifier R000024502, CTP 700272017 is getting wrongly attached with this CTP. Hence update accordingly.
    • 28 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top